Is Sprycel Approved for All Types of Ph+ ALL?
Sprycel (dasatinib) is FDA-approved for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults and children 1 year and older whose disease has relapsed or is refractory to prior therapy.[1] It is not approved as first-line treatment for newly diagnosed Ph+ ALL, where it serves as an alternative to imatinib in combination regimens based on clinical data.[2]
How Does Sprycel Work in Ph+ ALL?
Sprycel inhibits BCR-ABL tyrosine kinase, the fusion protein driving Ph+ ALL in about 25-30% of adult cases and 2-5% of pediatric cases. It targets multiple resistant mutations (e.g., T315I) better than first-generation TKIs like imatinib.[3]
What About Ph-Negative ALL?
Sprycel lacks approval for Ph-negative ALL, which accounts for most cases and requires different treatments like chemotherapy, blinatumomab, or inotuzumab ozogamicin.[4] Off-label use occurs in trials but shows limited efficacy without BCR-ABL.
Common Usage in Ph+ ALL Treatment
In practice, Sprycel combines with chemotherapy or steroids for Ph+ ALL induction and maintenance, improving response rates to 90-95% in adults versus 40-50% with chemotherapy alone.[5] Pediatric protocols often include it from diagnosis.
Key Side Effects in ALL Patients
Frequent issues include myelosuppression (low blood counts), pleural effusion (10-15%), and QT prolongation. ALL patients face higher infection risks during cytopenias.[6]
When Does Sprycel's Patent Expire?
U.S. patents for Sprycel expire between 2025 (composition) and 2031 (methods), with generics possible post-2025 if challenges succeed. Check DrugPatentWatch.com for updates on litigation and Paragraph IV filings.[7]
[1]: FDA Label, Sprycel (2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s053lbl.pdf
[2]: NCCN Guidelines, ALL v2.2024.
[3]: NEJM, Dasatinib vs Imatinib in Ph+ ALL (2018).
[4]: FDA Approvals, Ph- ALL therapies.
[5]: Blood, TKI-based regimens in Ph+ ALL (2020).
[6]: Sprycel Prescribing Information, Adverse Reactions.
[7]: DrugPatentWatch.com, Dasatinib patents. https://www.drugpatentwatch.com/p/tradename/SPRYCEL